September 10, 2020 -- Nestlé Health Science subsidiary ProciseDx has received the European CE Mark for Procise IFX and Procise ADL, the company's infliximab and adalimumab point-of-care diagnostics.
Procise IFX and Procise ADL provide diagnostic data for therapeutic drug monitoring within five minutes of a finger-prick blood sample, the company noted. Both tests run on the ProciseDx system, which is about the size of a shoe box.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current